Recent Updates
Recently added Catalysts

Q/C Technologies, Inc.

QCLSFDA catalysts, PDUFA dates & pipeline intelligence
$0.32
▲ +0.01 · +3.19%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full QCLS financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $0.3052W HIGH $8.17
Volume
3.74 M
Value Traded
1.27 M
Short % Float
11.59%
Days to Cover
6.2
-17.25%Week
-38.78%1 Month
-89.11%3 Month
-92.13%6 Month
-99.97%5 Year
-100%All Time

Cash Data

Unlock QCLS cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
2.62 M
EPS (TTM)
-2.02
P/E Ratio
-
Ent. Value
-6.84 M
Total Shares
8.19 M
Float Shares
7.84 M
Insiders
4.25%
Institutions
7.30%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Unlock every QCLS catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

QCLS Catalyst Timeline

Dated clinical, regulatory and corporate events for Q/C Technologies, Inc.

Unlock the full QCLS catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How QCLS actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
No matching catalysts
Unlock all QCLS historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

No drug pipeline

Q/C Technologies, Inc. is a diagnostics company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.

Clinical Trial Results

Readouts, endpoints and source filings for every QCLS program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
MYMD-1 sarcopeniaPhase 22023-10-04statistical significance in reducing serum levels of TNF- , IL-6 and sTNFR1; reduction in TNF- across 28 days versus placebo (p=0.002 to 0.008)Read MoreMyMD Pharmaceuticals to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF- Market Disrupter, at BioFuture 2023 - Company to share new positive, statistically significant results across CohoRead More
Scroll for more · summaries link to the source press release
Unlock every QCLS trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock QCLS insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Voss Chelsea SierraDirectorGrant/Award 50,000 50,000 held$0.00 04/13/2026
Unlock the full QCLS insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
No hedge fund reported a 13F position in QCLS for Q2 2026.
Unlock every fund holding QCLS
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in QCLS
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see QCLS ownership
Insider and institutional ownership, quarter by quarter.

QCLS Short Interest

Shares sold short, counted twice a month.

11.59%
Short % of Float
of tradable shares sold short
908.3K
Shares Sold Short
-8.9% vs prior count
6.2 High
Days to Cover
trading days of normal volume to buy every short share back
147.4K
Avg Daily Volume
the average used for days to cover
Unlock QCLS short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock QCLS option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live QCLS option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock QCLS options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How QCLS ranks across every disease it competes in

Competitive Position is a premium feature
See how QCLS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

QCLS News

QCLS
Nov 16, 2026
QCLSGeneral
▲ +3.2%today

Q/C Technologies Reports Over $10 Million in Cash and Investments to Fund Development of Its Optical Processing Unit

Q/C Technologies reported over $10 million in cash to fund its Optical Processing Unit (OPU) development. The OPU aims to enhance AI computations using light, targeting energy efficiency. Initial designs are expected by the end of 2026, with a hardware demonstration planned for 2027. The company is led by CTO Yossi Ehrlichman, who has significant expertise in optical computing.

Read more →
QCLS
Sep 30, 2026
QCLSGeneral

Q/C Technologies Announces Research Collaboration with Sandia National Laboratories, a $5 Billion U.S. Department of Energy Lab

Q/C Technologies has partnered with Sandia National Laboratories to advance its optical processing unit initiative for AI inference. This collaboration focuses on research in nanophotonics and aims to establish a roadmap for scalable optical AI processing. The company recently opened a new integrated photonics lab to support this initiative.

Read more →
QCLS
Sep 15, 2026
QCLSGeneral
▼ -21.2%on this news· ran to +72% by day 1

Q/C Technologies Names Yossef Ehrlichman Chief Technology Officer to Lead Optical Processor Development

Q/C Technologies appointed Yossef Ehrlichman as Chief Technology Officer to lead its optical processor development. Dr. Ehrlichman, with 15 years of experience, aims to enhance AI systems' energy efficiency and bandwidth. He will oversee the optical processing unit program, focusing on integrating optical processing and memory into computing platforms.

Read more →
QCLS
Aug 4, 2026
QCLSGeneral
▲ +6.5%on this news

Q/C Technologies Appoints Veteran Silicon Photonics Engineer Yossef Ehrlichman as Founding Manager, Photonic Integrated Circuit (PIC) Development

Q/C Technologies appointed Yossef Ehrlichman as Founding Manager for Photonic Integrated Circuit Development. He will lead the optical processing unit initiative, leveraging his 15 years of experience in silicon photonics. This appointment is part of the company's strategy to enhance its optical computing capabilities, addressing the demands of AI applications.

Read more →
QCLS
Jun 30, 2026
QCLSGeneral
▲ +5.4%on this news

Q/C Technologies Relocates Headquarters to San Francisco in Proximity to World-Class Engineering Experts for Photonic Computing and Optical AI Inference Initiative

Q/C Technologies has relocated its headquarters to San Francisco to enhance its optical computing initiatives. The move aims to facilitate the development of a proprietary optical processing unit (OPU) and to attract top engineering talent from the region. The company is building a 4,800-square-foot integrated photonics lab to advance its research and development efforts.

Read more →
QCLS
Mar 18, 2026
QCLSGeneral

Q/C Technologies Launches Optical Processing Unit (OPU) Initiative to Develop Proprietary Silicon Photonic Computing Architecture for AI Inference

Q/C Technologies has launched an initiative to develop a proprietary optical processing unit aimed at enhancing AI inference capabilities. This initiative seeks to address the performance and energy limitations of traditional electronic architectures by utilizing optical computing. The company is assembling a specialized engineering team and plans to file foundational patents as part of the development process.

Read more →
QCLS
Jan 20, 2026
QCLSGeneral

Technologies Appoints AI Systems Leader Chelsea Voss to Board of Directors

Q/C Technologies announced the appointment of Chelsea Voss to its Board of Directors, effective January 20, 2026. Voss, a computer scientist at OpenAI, brings expertise in machine learning and AI systems development. The company is focusing on advancing its quantum-class laser processing units (qc-LPU) through partnerships aimed at enhancing photonic computing capabilities. However, Q/C Technologies must navigate risks related to product development and market conditions as it seeks to innovate in energy-efficient computing.

Read more →
QCLS
Dec 9, 2025
QCLSGeneral

Quantum-Class Computing Developer Q/C Technologies Welcomes Strategic Advisor Martin Shkreli New York

Q/C Technologies, Inc. (Nasdaq: QCLS) has announced the appointment of Martin Shkreli as a Strategic Advisor, adding depth to its advisory team. Shkreli, alongside advisor James Altucher, is expected to contribute insights into technology, industry contacts, and financial innovation. The company's quantum-class computing technology, which emphasizes optical advancements, aims to deliver exceptional performance while being energy efficient. Q/C's proprietary qc-LPU100 products are reported to outperform current GPUs and quantum computers significantly, utilizing 100 times less energy.

Read more →
QCLS
Oct 30, 2025
QCLSGeneral
▼ -11.1%on this news

Q/C Technologies Introduces Proprietary qc-LPU100™ Brand of Quantum-Class Laser Processing Units

Q/C Technologies announced the qc-LPU100, a quantum-class laser processing unit designed to compute at unprecedented speeds using natural light. This technology aims to outperform traditional GPUs and quantum computers while addressing energy consumption and scalability issues. The collaboration with LightSolver is expected to enhance performance in crypto mining and AI applications.

Read more →
QCLS
Oct 16, 2025
QCLSGeneral
▲ +16%on this news

Q/C Technologies Appoints Technion Professor Dr. Steven Frankel as Senior Quantum Advisor to Advance Photonic and Quantum-Class Computing Initiatives

Q/C Technologies appointed Dr. Steven Frankel as Senior Quantum Advisor to enhance its quantum-class photonic computing initiatives. Dr. Frankel, with extensive expertise in quantum technologies, will guide the development of Q/C's Laser Processing Unit. His role aims to accelerate commercialization and improve high-performance computing solutions.

Read more →
QCLS
Sep 26, 2025
QCLSGeneral

Technologies (Formerly TNF Pharmaceuticals) Commences Trading on Nasdaq Under New Ticker Symbol "QCLS" technology positions Company at forefront of new quantum-class computing paradigm

Q/C Technologies, previously known as TNF Pharmaceuticals, has commenced trading on Nasdaq under the ticker symbol QCLS. The name change reflects the company's strategic pivot towards quantum-class computing, with exclusive rights to LightSolver's laser-based processing technology for cryptocurrency applications. This transition marks a significant milestone for the company, as it aims to leverage its innovative technology to provide high-speed computing solutions. Company leadership is optimistic about the potential for sustainable value for shareholders as they advance their first-mover strategy in the industry.

Read more →
QCLS
Sep 24, 2025
QCLSGeneral

TNF Pharmaceuticals Announces Name Change to Q/C Technologies and New Ticker Symbol “QCLS” to Reflect Strategic Focus on Quantum Class Photonic Computing

TNF Pharmaceuticals has rebranded as Q/C Technologies, effective September 25, 2025, and will trade under the ticker QCLS. The name change reflects a strategic shift towards quantum-class computing, particularly in the cryptocurrency sector, leveraging LightSolver's laser processing technology. This innovation aims to enhance performance and sustainability in blockchain applications.

Read more →
QCLS
Sep 17, 2025
QCLSGeneral

TNF Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

TNF Pharmaceuticals Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement. The company maintained a bid price of $1.00 for 10 consecutive business days. Executive Chairman Joshua Silverman expressed satisfaction with this milestone and indicated plans for future updates to shareholders.

Read more →
QCLS
Sep 8, 2025
QCLSConferences/Events

TNF Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference

TNF Pharmaceuticals will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025, at 8:00 a.m. ET. The event will take place at the Lotte New York Palace Hotel in New York City. Management will also hold one-on-one investor meetings during the conference.

Read more →
QCLS
Sep 4, 2025
QCLSGeneral

Pharmaceuticals Announces Closing of $7 Million Private Placement

TNF Pharmaceuticals has successfully closed a $7 million private placement financing of convertible preferred stock, priced at a 44% premium to market. This funding involved participation from TNF's largest strategic stockholder and other existing stockholders. The capital raised is earmarked to support key development milestones for TNF's newly licensed light-based computing accelerator technology. TNF's leadership expressed optimism about the financing, viewing it as a vote of confidence in their strategy and value proposition.

Read more →
QCLS
Sep 2, 2025
QCLSGeneral

Pharmaceuticals Secures Exclusive Global Rights to Innovative Light Speed Computing Accelerator for Use in Cryptocurrency Applications

TNF Pharmaceuticals has secured exclusive global rights to a light-speed computing accelerator for cryptocurrency applications through a partnership with LightSolver. This technology, which aims to outperform conventional computing methods and reduce energy costs significantly, positions TNF for substantial growth in a burgeoning market. Notably, TNF plans to undergo a name change to reflect its new focus. The partnership is expected to unlock new efficiencies in blockchain technology and respond to the industry's demand for more effective computing solutions.

Read more →
QCLS
Aug 28, 2025
QCLSGeneral

TNF Pharmaceuticals Announces Reverse Stock Split For Nasdaq Listing Compliance

TNF Pharmaceuticals announced a reverse stock split at a ratio of 1-for-100 to comply with Nasdaq listing requirements. The split will reduce the number of outstanding shares significantly, from approximately 178.6 million to 1.8 million. Trading on a split-adjusted basis will commence on September 2, 2025.

Read more →
QCLS
Aug 19, 2025
QCLSGeneral

TNF Pharmaceuticals Strengthens Financial Position for Growth and Value Creation

TNF Pharmaceuticals has improved its financial position by significantly reducing liabilities while maintaining over $17 million in total assets. This positive change is expected to provide a stronger platform for growth and shareholder value creation. The company is also collaborating with Renova on research related to inflammation and muscle damage.

Read more →
QCLS
Jun 24, 2025
QCLSGeneral

TNF Pharmaceuticals Collaborates with DADA2 Foundation for Compassionate Use Study of Isomyosamine in Rare Pediatric Autoinflammatory Disease

TNF Pharmaceuticals has partnered with the DADA2 Foundation to conduct a Compassionate Use study of isomyosamine, a novel TNF-alpha inhibitor. This collaboration aims to provide a new treatment option for DADA2, a rare autoinflammatory disease affecting children. Isomyosamine may offer advantages over traditional biologics, including oral administration and reduced immunosuppression.

Read more →
QCLS
May 8, 2025
QCLSGeneral

TNF Pharmaceuticals and Renova Health Report Positive Results in Identifying Targets for Treating TNF-Driven Inflammation in Patients Receiving GLP-1 Agonists

TNF Pharmaceuticals and Renova Health reported positive findings from a study on patients using GLP-1 agonists. The study aims to evaluate isomyosamine's effects on inflammation and muscle mass preservation. Initial data suggests opportunities for better diagnosis and treatment of inflammation-related conditions. The research could significantly impact patient care in outpatient settings.

Read more →

About Q/C Technologies, Inc.

New York, NY 2 employees qctechnologies.com
Headquarters1185 AVENUE OF THE AMERICAS, NEW YORK, NY, 10036
BIOPHARMAWATCH ELITE
Trade the next QCLS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime